Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bearing lung tumors with resistance mutations. AZD9291 showed substantial tumor shrinkage in both groups of mice after 14 days of treatment. After 40 days, the researchers found no visible tumors in these mice, and this effect was sustained for more than 100 days. They also observed similar tumor shrinkage in mice that were genetically modified to develop tumors bearing both the activating and resistance mutations.

When the investigators analyzed blood samples collected from the treated mice, they identified a breakdown product of the parent compound AZD9291, which they called AZ5104, circulating in blood in addition to AZD9291. They then found that AZ5104 is also a potent inhibitor of activating and resistance EGFR mutations, and speculated that this may contribute to the efficacy seen after dosing with AZD9291.

Using data from blood analyses of mice, the researchers then developed a mathematical model to evaluate the dynamics of conversion of AZD9291 to AZ5104 and cumulative tumor-inhibitory effects. These experiments helped them determine the potentially effective doses of AZD9291 for patients with NSCLC harboring both activating and resistance EGFR mutations.

"Findings from preclinical studies have recently been translated to the clinic, where the drug has already demonstrated tumor shrinkage in patients and has been well tolerated, with low rates of side effects," said Galbraith. "The degree of response to treatment with AZD9291 in such a short period of time is very exciting. This new drug has the potential to provide new treatment options for patients in this setting."


'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in the ... and along with that; a humdinger of an allergy season. A relief from drought ... increase in misery-causing grass and weed pollen. , “Our patients have been reporting ...
(Date:6/24/2017)... ... 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) ... Erie Convention Center on June 8-10. The weekend consisted of many educational ... and scholarship presentations, and professional networking. , On Friday June 9th, PATS ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran Y. Rubinstein ... recently begun offering three new minimally invasive procedures to patients who want a ... downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... essential, and two new videos highlight the importance of correctly using a meat ... Ph.D., who has done extensive research on consumer food safety habits. Dr. Bruhn ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
(Date:5/18/2017)... 2017  Two Bayer U.S. Pharmaceutical leaders received top ... recent 28 th Woman of the Year ... HBA,s longstanding mission of furthering the advancement and impact ... Cindy Powell-Steffen , senior director of brand activation ... Libby Howe , a regional business manager for ...
(Date:5/15/2017)... ATLANTA , May 15, 2017  Amy Baxter ... the industry leader in noninvasive pain relief, was awarded ... MM&M magazine. Baxter was recognized at the MM&M ... New York City on May 10, ... helping the biopharma industry go "beyond the pill."  ...
Breaking Medicine Technology: